How many organs could you donate and remain alive? How many planet Earths could fit inside the Sun? How high is a giraffe's blood pressure? Why is the sea blue? To find out, Ask The Naked Scientists!
…
continue reading
محتوای ارائه شده توسط Jon Chee. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط Jon Chee یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Player FM - برنامه پادکست
با برنامه Player FM !
با برنامه Player FM !
🧬 Doug Drysdale - Cybin - Part 4 | The Challenges of Running a Public Company | Transforming Psychiatric Treatments Through Psychedelic Compounds | Developing Breakthrough Therapies in Depression & Anxiety
Manage episode 438336943 series 3461709
محتوای ارائه شده توسط Jon Chee. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط Jon Chee یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.
Part 4 of 4.
Part 4 of 4.
My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics.
Doug is an experienced investor, Corporate Director and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During his 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents and has raised and invested around $4 billion of both public and private capital.
Before Cybin, Doug was Commercial Products Manager at DuPont Merck, Director of BD at Elan, VP of M&A at Actavis Group, CEO of Norwich Pharmaceuticals and Alvogen, CEO of Pernix Therapeutics, and CEO of Tedor Pharma. His extensive background as a seasoned executive, investor, and turn-around specialist gives him a wide range of experiences that founders can learn from.
Join us this week and hear about:
- Doug’s first-time experience running a public company: the challenges of hitting quarterly numbers and juggling the pressure of share price volatility
- His move to Cybin, a startup transforming psychiatric treatments through psychedelic compounds
- Cybin’s recent progress, including some key acquisitions, taking the company public, and their breakthrough therapies in depression and anxiety.
Please enjoy my conversation with Doug Drysdale.
Timestamps:
00:28 Intro
01:50 Doug’s first experience running a public company, Pernix Therapeutics
06:51 Leaving Pernix for a private company and a break from public scrutiny
08:22 Joining Cybin, going public, and raising $300MM; quickly developing therapy and IP assets
11:34 Cybin’s mission and focus; the co-founders and the team behind the technology
15:08 The DEA’s outlook on psychedelics and the development of SSRI alternatives
17:26 Doug’s experience working with the FDA
19:39 Cybin’s IP and partnership strategies; building out a core team and retaining talent
24:00 Cybin’s 2-year vision
24:58 Shoutouts and advice to 21-year old self
26:37 Outro
Find Our Guest, Doug Drysdale, at these links:
Find Our Host, Jon Chee, at these links:
Social & Website
LinkedIn: https://www.linkedin.com/company/excedr/
Youtube: https://www.youtube.com/@excedr
Instagram: https://www.instagram.com/excedr_inc
Twitter: https://twitter.com/ExcedrInc
Facebook: https://www.facebook.com/excedr
TikTok: https://www.tiktok.com/@excedr
Podcast Website: https://www.thebiotechstartupspodcast.com/
Enriched Notes:
Topics Mentioned:
Pernix Therapeutics: https://en.wikipedia.org/wiki/Pernix_Therapeutics_Holdings
Cybin: https://cybin.com/
Intellectual Property 101: https://www.excedr.com/resources/intellectual-property-guide
Psychedelic Compounds for Therapies: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592297/
Pharmacokinetics: https://www.ncbi.nlm.nih.gov/books/NBK557744/
Understanding Psilocybin and DMT Treatments for Depression: https://www.hopkinsmedicine.org/news/newsroom/news-releases/2022/02/psilocybin-treatment-for-major-depression-effective-for-up-to-a-year-for-most-patients-study-shows
Cybin’s Developmental Pipeline: https://cybin.com/development-pipeline/
DEA’s outlook on psychedelics: https://www.cato.org/regulation/spring-2023/psychedelics-dea-regulating-religion
Guide to FDA Drug Approval Process: https://www.excedr.com/blog/fda-drug-approval-process-guide
IP Strategy for Biotechs: https://www.excedr.com/resources/intellectual-property-strategy-for-biotechs
Biotech Partnerships: https://www.excedr.com/blog/how-biotech-partnerships-support-research
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
78 قسمت
Manage episode 438336943 series 3461709
محتوای ارائه شده توسط Jon Chee. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط Jon Chee یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.
Part 4 of 4.
Part 4 of 4.
My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics.
Doug is an experienced investor, Corporate Director and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During his 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents and has raised and invested around $4 billion of both public and private capital.
Before Cybin, Doug was Commercial Products Manager at DuPont Merck, Director of BD at Elan, VP of M&A at Actavis Group, CEO of Norwich Pharmaceuticals and Alvogen, CEO of Pernix Therapeutics, and CEO of Tedor Pharma. His extensive background as a seasoned executive, investor, and turn-around specialist gives him a wide range of experiences that founders can learn from.
Join us this week and hear about:
- Doug’s first-time experience running a public company: the challenges of hitting quarterly numbers and juggling the pressure of share price volatility
- His move to Cybin, a startup transforming psychiatric treatments through psychedelic compounds
- Cybin’s recent progress, including some key acquisitions, taking the company public, and their breakthrough therapies in depression and anxiety.
Please enjoy my conversation with Doug Drysdale.
Timestamps:
00:28 Intro
01:50 Doug’s first experience running a public company, Pernix Therapeutics
06:51 Leaving Pernix for a private company and a break from public scrutiny
08:22 Joining Cybin, going public, and raising $300MM; quickly developing therapy and IP assets
11:34 Cybin’s mission and focus; the co-founders and the team behind the technology
15:08 The DEA’s outlook on psychedelics and the development of SSRI alternatives
17:26 Doug’s experience working with the FDA
19:39 Cybin’s IP and partnership strategies; building out a core team and retaining talent
24:00 Cybin’s 2-year vision
24:58 Shoutouts and advice to 21-year old self
26:37 Outro
Find Our Guest, Doug Drysdale, at these links:
Find Our Host, Jon Chee, at these links:
Social & Website
LinkedIn: https://www.linkedin.com/company/excedr/
Youtube: https://www.youtube.com/@excedr
Instagram: https://www.instagram.com/excedr_inc
Twitter: https://twitter.com/ExcedrInc
Facebook: https://www.facebook.com/excedr
TikTok: https://www.tiktok.com/@excedr
Podcast Website: https://www.thebiotechstartupspodcast.com/
Enriched Notes:
Topics Mentioned:
Pernix Therapeutics: https://en.wikipedia.org/wiki/Pernix_Therapeutics_Holdings
Cybin: https://cybin.com/
Intellectual Property 101: https://www.excedr.com/resources/intellectual-property-guide
Psychedelic Compounds for Therapies: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592297/
Pharmacokinetics: https://www.ncbi.nlm.nih.gov/books/NBK557744/
Understanding Psilocybin and DMT Treatments for Depression: https://www.hopkinsmedicine.org/news/newsroom/news-releases/2022/02/psilocybin-treatment-for-major-depression-effective-for-up-to-a-year-for-most-patients-study-shows
Cybin’s Developmental Pipeline: https://cybin.com/development-pipeline/
DEA’s outlook on psychedelics: https://www.cato.org/regulation/spring-2023/psychedelics-dea-regulating-religion
Guide to FDA Drug Approval Process: https://www.excedr.com/blog/fda-drug-approval-process-guide
IP Strategy for Biotechs: https://www.excedr.com/resources/intellectual-property-strategy-for-biotechs
Biotech Partnerships: https://www.excedr.com/blog/how-biotech-partnerships-support-research
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
78 قسمت
همه قسمت ها
×به Player FM خوش آمدید!
Player FM در سراسر وب را برای یافتن پادکست های با کیفیت اسکن می کند تا همین الان لذت ببرید. این بهترین برنامه ی پادکست است که در اندروید، آیفون و وب کار می کند. ثبت نام کنید تا اشتراک های شما در بین دستگاه های مختلف همگام سازی شود.